Santiago García-López1, Judith Millastre Bocos1, Javier P Gisbert2, Eduardo Bajador1, María Chaparro2, Carlos Castaño2, José A García-Erce3, Fernando Gomollón4. 1. Department of Gastroenterology, University Hospital "Miguel Servet", Zaragoza, Spain. 2. Department of Gastroenterology, University Hospital "La Princesa", Institute of Health Investigation La Princesa (IP), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain. 3. Department of Haematology and Haemotherapy, Hospital San Jorge, IdiPAZ-49 Aragon Institute of Health Institute, Huesca, Spain. 4. Department of Gastroenterology, Hospital Clinic University "Lozano Blesa", IIS Aragón, CIBERehd, Zaragoza, Spain.
Abstract
BACKGROUND: Anaemia and iron deficiency are very common in inflammatory bowel disease. Clinical trials have shown intravenous iron to be effective and well tolerated. However, published experience in clinical practice with specific evaluation of the effect on quality of life is limited. MATERIAL AND METHODS: We carried out a prospective, multicentre, observational study on the effects of ferric carboxymaltose in the treatment of iron deficiency anaemia in inflammatory bowel disease. Anaemia and iron deficiency were defined according to World Health Organization criteria. Efficacy and safety were evaluated at infusion, at 2 weeks and at 12 weeks. Quality of life was evaluated according to the SIBDQ-9 index. Complete response was defined as anaemia correction or more tan 2 g/dL increase in haemoglobin. RESULTS: A total of 88 courses of ferric carboxymaltose in 72 patients were evaluated. Complete response was observed in 46% of patients at week 2, and 81.2% at week 12. Quality of life improved significatively at week 2 in both complete responders and partial responders (p<0.0005); complete responders showed siginficantly better response (p=0.016). No predictive factor was identified. Only one transient adverse effect was observed; however, this was severe. DISCUSSION: Ferric carboxymaltose showed comparable efficacy to that demonstrated in clinical trials. After only two weeks of treatment, there was a significant improvement in quality of life, with a greater effect observed in those patients with a complete haematologic response. Intravenous iron can very quickly improve quality of life in inflammatory bowel disease.
BACKGROUND:Anaemia and iron deficiency are very common in inflammatory bowel disease. Clinical trials have shown intravenous iron to be effective and well tolerated. However, published experience in clinical practice with specific evaluation of the effect on quality of life is limited. MATERIAL AND METHODS: We carried out a prospective, multicentre, observational study on the effects of ferric carboxymaltose in the treatment of iron deficiency anaemia in inflammatory bowel disease. Anaemia and iron deficiency were defined according to World Health Organization criteria. Efficacy and safety were evaluated at infusion, at 2 weeks and at 12 weeks. Quality of life was evaluated according to the SIBDQ-9 index. Complete response was defined as anaemia correction or more tan 2 g/dL increase in haemoglobin. RESULTS: A total of 88 courses of ferric carboxymaltose in 72 patients were evaluated. Complete response was observed in 46% of patients at week 2, and 81.2% at week 12. Quality of life improved significatively at week 2 in both complete responders and partial responders (p<0.0005); complete responders showed siginficantly better response (p=0.016). No predictive factor was identified. Only one transient adverse effect was observed; however, this was severe. DISCUSSION: Ferric carboxymaltose showed comparable efficacy to that demonstrated in clinical trials. After only two weeks of treatment, there was a significant improvement in quality of life, with a greater effect observed in those patients with a complete haematologic response. Intravenous iron can very quickly improve quality of life in inflammatory bowel disease.
Authors: Ragnar Befrits; Ola Wikman; Lars Blomquist; Henrik Hjortswang; Per Hammarlund; Antal Bajor; Daniel Klintman; Håkan Blom Journal: Scand J Gastroenterol Date: 2013-07-29 Impact factor: 2.423
Authors: C Gasché; C Dejaco; T Waldhoer; W Tillinger; W Reinisch; G F Fueger; A Gangl; H Lochs Journal: Ann Intern Med Date: 1997-05-15 Impact factor: 25.391
Authors: Jose María Huguet; Xavier Cortés; Marta Maia Boscá-Watts; Margarita Muñoz; Nuria Maroto; Marisa Iborra; Esther Hinojosa; María Capilla; Carmina Asencio; Cirilo Amoros; Jose María Paredes Journal: J Clin Med Date: 2022-05-15 Impact factor: 4.964
Authors: Svein Oskar Frigstad; Anne Haaber; Antal Bajor; Jan Fallingborg; Per Hammarlund; Ole K Bonderup; Håkan Blom; Terje Rannem; Per M Hellström Journal: Gastroenterol Res Pract Date: 2017-10-22 Impact factor: 2.260